Multiple sclerosis (MS) is a disease that affects the brain and spinal cord. It can cause fatigue, trouble with balance and coordination, muscle weakness, and vision problems. Having MS doesn’t ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Physical activity was associated with a lower risk of disability progression in multiple sclerosis (MS), longitudinal data showed. Compared with low physical activity, the risk of confirmed disability ...

Higher consumption of oily fish such as tuna and salmon or lean fish like cod and perch is associated with a reduced risk for disability progression in patients with multiple sclerosis (MS), a new ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...

COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). The Phase 3 HERCULES ...

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

Racial and ethnic differences in the severity, prognosis, and mortality of multiple sclerosis (MS) have been the focus of intensifying research over the last decade, and emerging evidence suggests ...

The largest study of its kind has found menopause is not associated with an increased risk of disability in women with multiple sclerosis (MS). Until now, the impact of reduced sex hormones on women ...